公开(公告)号：DE69834263D1

公开(公告)日：2006-05-24

申请号：DE69834263

申请日：1998-09-24

Applicant: MONASH UNIVERSITY CLAYTON

Inventor： SMALL HENRY ,  SAEZ-VALERO JAVIER ,  SBERNA GIAN

IPC: C12Q1/46 ,  G01N33/573 ,  C12N9/16 ,  C12N9/18 ,  G01N33/68

公开(公告)号：DE69929173D1

公开(公告)日：2006-02-02

申请号：DE69929173

申请日：1999-01-29

Applicant: MONASH UNIVERSITY CLAYTON ,  NEURO THERAPEUTICS LTD

Inventor： JACKSON WILLIAM ,  SUBASINGHE RUPIKA ,  BOURA LOUIS

IPC: C07D221/26 ,  A61K31/435 ,  A61K31/445 ,  A61K31/451 ,  A61K31/472 ,  A61K31/485 ,  A61K47/48 ,  A61P25/04 ,  C07D211/32 ,  C07D211/64 ,  C07D221/28 ,  C07D223/06 ,  C07D223/14 ,  C07D489/02 ,  C07D489/04 ,  C07D489/08 ,  C07D489/12

公开(公告)号：AU2002951215A0

公开(公告)日：2002-09-19

申请号：AU2002951215

申请日：2002-09-04

Applicant: MONASH UNIVERSITY MOONBUSH PTY

IPC: A61K38/00 ,  A61P3/10 ,  A61P5/00 ,  A61P7/00 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61P43/00 ,  C07K5/078

公开(公告)号：DE69231291D1

公开(公告)日：2000-08-31

申请号：DE69231291

申请日：1992-03-25

Applicant: CSL LTD ,  MONASH UNIVERSITY CLAYTON

Inventor： BARR GEORGE ,  THIEL JAMES

IPC: A61K9/00 ,  A61K9/22 ,  A61K9/32 ,  A61K9/50 ,  A61K31/70 ,  A61K35/12 ,  A61K38/00 ,  A61K38/22 ,  A61K39/00 ,  A61K39/08 ,  A61K35/18 ,  A61K39/02 ,  A61K39/39

Abstract: PCT No. PCT/AU92/00124 Sec. 371 Date Nov. 17, 1993 Sec. 102(e) Date Nov. 17, 1993 PCT Filed Mar. 25, 1992 PCT Pub. No. WO92/17165 PCT Pub. Date Oct. 15, 1992The invention provides a pharmaceutical or veterinary implant, which when parenterally administered releases a pulse of at least one biologically active material at a controllable time interval after implantation. The implant comprises the biologically active material; an excipient comprising at least one water soluble material and at least one water insoluble material; and a polymer film coating adapted to rupture at a predetermined period of time after implantation, and wherein the excipients and polymers are biocompatible. The biologically active material is selected from the group consisting of antigens, antibodies, hormones, growth promotants, antibiotics, nutrients, minerals and vitamins. Preferably the excipient comprises a combination of two or more water-soluble and water-insoluble materials.

公开(公告)号：NZ242065A

公开(公告)日：1996-06-25

申请号：NZ24206592

申请日：1992-03-19

Applicant: CSL LTD ,  MONASH UNIVERSITY SUBSTITUTED ,  VICTORIAN COLLEGE OF PHARMACY

Inventor： BARR IAN GEORGE ,  THIEL WILLIAM JAMES

IPC: A61K9/00 ,  A61K9/22 ,  A61K9/32 ,  A61K9/50 ,  A61K31/70 ,  A61K35/12 ,  A61K38/00 ,  A61K38/22 ,  A61K39/00 ,  A61K9/52 ,  A61K9/30

Abstract: PCT No. PCT/AU92/00124 Sec. 371 Date Nov. 17, 1993 Sec. 102(e) Date Nov. 17, 1993 PCT Filed Mar. 25, 1992 PCT Pub. No. WO92/17165 PCT Pub. Date Oct. 15, 1992The invention provides a pharmaceutical or veterinary implant, which when parenterally administered releases a pulse of at least one biologically active material at a controllable time interval after implantation. The implant comprises the biologically active material; an excipient comprising at least one water soluble material and at least one water insoluble material; and a polymer film coating adapted to rupture at a predetermined period of time after implantation, and wherein the excipients and polymers are biocompatible. The biologically active material is selected from the group consisting of antigens, antibodies, hormones, growth promotants, antibiotics, nutrients, minerals and vitamins. Preferably the excipient comprises a combination of two or more water-soluble and water-insoluble materials.

公开(公告)号：AU636318B2

公开(公告)日：1993-04-29

申请号：AU4590089

申请日：1989-12-04

Applicant: MONASH UNIVERSITY

Inventor： DAVID MARK MILNE-ROBERTSON ,  DAVID MORRITZ DE KRETSER ,  MILTON THOMAS WILLIAM HEARN ,  HENRY GEORGE BURGER ,  JOHN KERR FINDLAY ,  FRANCIS JOSEPH MORGAN ,  ROBERT GREGORY FORAGE ,  RICHARD EDWARD HUGH WETTENHALL

IPC: A61K20060101 ,  C07K20060101 ,  C12P21/08 ,  C12Q1/68 ,  G01N20060101 ,  G01N33/53 ,  G01N33/68 ,  G01N33/74

公开(公告)号：DE2901723C2

公开(公告)日：1986-04-17

申请号：DE2901723

申请日：1979-01-17

Applicant: MONASH UNIVERSITY, CLAYTON, VICTORIA, AU

Inventor： POTTER, OWEN EDWARD, CAMBERWELL, VICTORIA, AU

IPC: F26B3/084 ,  F26B23/10 ,  F26B3/08

公开(公告)号：DE69919885T2

公开(公告)日：2005-09-15

申请号：DE69919885

申请日：1999-10-20

Applicant: MONASH UNIVERSITY CLAYTON

Inventor： DOPHEIDE MARIE ,  COOKE MARK ,  JACKSON PHILLIP

IPC: G01N33/49 ,  C12M1/00 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/543 ,  G01N33/554 ,  G01N33/566 ,  F26B9/04 ,  G01N33/88

公开(公告)号：DE02740997T1

公开(公告)日：2004-07-15

申请号：DE02740997

申请日：2002-06-27

Applicant: MONASH UNIVERSITY CLAYTON

Inventor： COMPER D

IPC: G01N27/62 ,  C12Q1/37 ,  G01N27/447 ,  G01N27/64 ,  G01N30/26 ,  G01N30/34 ,  G01N30/74 ,  G01N30/88 ,  G01N33/68

Abstract: The invention provides a method of generating and analyzing a urinary protein fragmentation profile, in terms of the size, and sequence of particular fragments derived from intact filtered proteins together with the position where enzymes scission occurs along the protein polypeptide chain is characteristic of the diseased state of the kidney. With the recognition that filtered proteins are degraded during renal passage, the methods described in this application will be able to detect protein fragments derived from proteins generated by non-renal disease. Non-renal disease such as cancers may generate increased levels of proteins into the circulation. The urinary analysis of these filtered proteins would currently not detect the intact form of these proteins. Therefore, a method as described to detect and analyze fragments resulting from degradation during renal passage that will be able to detect the seriousness of the disease.

公开(公告)号：AU2003901144A0

公开(公告)日：2003-03-27

申请号：AU2003901144

申请日：2003-03-13

Applicant: MONASH UNIVERSITY SCHOOL OF CH

IPC: H01G9/038 ,  H01G9/155 ,  H01M10/052 ,  H01M10/0563 ,  H01M10/0565 ,  H01M10/26 ,  H01M10/36 ,  H01M10/40

Abstract: Pyrrolidinium based room temperature ionic liquids, and phosphorous and arsenic analogues, are used as electrolytes in energy storage devices including secondary lithium batteries, supercapacitors and asymmetric battery-supercapacitors. The electrolytes preferably contain lithium ions as the charge-carrying species. The electrolytes are in a liquid state at the operating temperature.